AstraZeneca Announces Director Share Acquisitions
Why we think this is neutral
This is a routine regulatory announcement regarding the vesting of deferred bonus plan awards for AstraZeneca's CEO and CFO. The transaction does not appear to have any material financial impact on the company.
Key Points
- CEO Pascal Soriot acquired 17,605 shares
- CFO Aradhana Sarin acquired 2,049 shares
Summary
The biopharmaceutical company has announced that certain senior executives have acquired shares in the business through a deferred bonus plan.
AstraZeneca PLC has announced that the company's Chief Executive Officer, Pascal Soriot, and Chief Financial Officer, Aradhana Sarin, have acquired ordinary shares in the company. The shares were acquired through the vesting of awards under the AstraZeneca Deferred Bonus Plan, which was granted in 2022 following the deferral of a portion of each PDMR's annual bonus in respect of 2021 performance.
DIRECTOR DEALINGS